Weight Loss Drugs and the Future of Weight Management and Wellbeing

Weight Loss Drugs and the Future of Weight Management and Wellbeing

2023 saw surging interest in weight loss driven by the rise of GLP-1 medications, with prescription drugs like Ozempic and Wegovy creating headlines during the year. Demand will continue to be strong in 2024, driven by the efficacy of these approaches, with double-digit percentage weight loss results, as well as buzz via social media. This briefing discusses the impact of GLP-1s on the weight management and wellbeing industry, and considers responses to the threat they represent.

Euromonitor International’s Weight Loss Drugs and the Future of Weight Management and Wellbeing global briefing examines the size, growth trends and potential opportunities in the Consumer Health market.  The strategic analyses include assessing the impacts of changing regulations, research breakthroughs and public health concerns on both the market and leading companies.  Consumer attitudes towards the products and their personal healthcare needs are also explored.

Product coverage: Allergy Care, Herbal/Traditional Products, OTC, Paediatric Consumer Health, Sports Nutrition, Vitamins and Dietary Supplements, Weight Management and Wellbeing.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Consumer Health market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.